These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 29495016)
41. The Adolescent Cannabis Problems Questionnaire (CPQ-A): psychometric properties. Martin G; Copeland J; Gilmour S; Gates P; Swift W Addict Behav; 2006 Dec; 31(12):2238-48. PubMed ID: 16626880 [TBL] [Abstract][Full Text] [Related]
42. Psychometric assessment of the marijuana adolescent problem inventory. Knapp AA; Babbin SF; Budney AJ; Walker DD; Stephens RS; Scherer EA; Stanger C Addict Behav; 2018 Apr; 79():113-119. PubMed ID: 29288984 [TBL] [Abstract][Full Text] [Related]
43. Psychometric Properties of the Turkish Versions of the Cannabis Use Problems Identification Test (CUPIT) and the Adult Cannabis Problems Questionnaire (CPQ). Evren C; Yilmaz Cengel H; Bozkurt M; Evren B; Umut G; Agachanli R J Psychoactive Drugs; 2017; 49(1):83-89. PubMed ID: 28195831 [TBL] [Abstract][Full Text] [Related]
44. Psychometric properties of the Center for Epidemiologic Studies Depression Scale (CES-D) in French clinical and nonclinical adults. Morin AJ; Moullec G; Maïano C; Layet L; Just JL; Ninot G Rev Epidemiol Sante Publique; 2011 Oct; 59(5):327-40. PubMed ID: 21925817 [TBL] [Abstract][Full Text] [Related]
45. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Adamson SJ; Kay-Lambkin FJ; Baker AL; Lewin TJ; Thornton L; Kelly BJ; Sellman JD Drug Alcohol Depend; 2010 Jul; 110(1-2):137-43. PubMed ID: 20347232 [TBL] [Abstract][Full Text] [Related]
46. Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire. Feingold D; Gliksberg O; Brill S; Amit BH; Lev-Ran S; Kushnir T; Sznitman SR Addict Behav; 2024 Nov; 158():108122. PubMed ID: 39128420 [TBL] [Abstract][Full Text] [Related]
47. Cannabis expectancies in substance misusers: French validation of the Marijuana Effect Expectancy Questionnaire. Guillem E; Notides C; Vorspan F; Debray M; Nieto I; Leroux M; Lépine JP Am J Addict; 2011; 20(6):543-54. PubMed ID: 21999501 [TBL] [Abstract][Full Text] [Related]
48. Cannabis use correlates with schizotypy in healthy people. Williams JH; Wellman NA; Rawlins JN Addiction; 1996 Jun; 91(6):869-77. PubMed ID: 8696249 [TBL] [Abstract][Full Text] [Related]
49. Confirmatory factor analysis and factorial invariance analysis of the adolescent self-report Strengths and Difficulties Questionnaire: how important are method effects and minor factors? van de Looij-Jansen PM; Goedhart AW; de Wilde EJ; Treffers PD Br J Clin Psychol; 2011 Jun; 50(2):127-44. PubMed ID: 21545447 [TBL] [Abstract][Full Text] [Related]
50. Problems with the identification of 'problematic' cannabis use: examining the issues of frequency, quantity, and drug use environment. Asbridge M; Duff C; Marsh DC; Erickson PG Eur Addict Res; 2014; 20(5):254-67. PubMed ID: 25196945 [TBL] [Abstract][Full Text] [Related]
51. Changes in cannabis use in Spanish consumers during the COVID-19 lockdown according to gender, age, living situation and addiction level. Villanueva Blasco VJ; González Amado B; Villanueva Silvestre V; Vázquez-Martínez A; Isorna Folgar M Adicciones; 2024 Jun; 36(2):217-226. PubMed ID: 36975073 [TBL] [Abstract][Full Text] [Related]
52. [Screening tools for cannabis use disorders and their adaptation to DSM-5: A literature review]. Artigaud L; Fener C; Bisch M; Schwan R; Schwitzer T; De Ternay J; Adamson SJ; Rolland B; Laprévote V Encephale; 2020 Oct; 46(5):382-389. PubMed ID: 32475691 [TBL] [Abstract][Full Text] [Related]
53. Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment. Connor JP; Gullo MJ; Feeney GF; Young RM Drug Alcohol Depend; 2011 Jun; 115(3):167-74. PubMed ID: 21163593 [TBL] [Abstract][Full Text] [Related]
54. Is the General Self-Efficacy Scale a Reliable Measure to be used in Cross-Cultural Studies? Results from Brazil, Germany and Colombia. Damásio BF; Valentini F; Núñes-Rodriguez SI; Kliem S; Koller SH; Hinz A; Brähler E; Finck C; Zenger M Span J Psychol; 2016 May; 19():E29. PubMed ID: 27225231 [TBL] [Abstract][Full Text] [Related]
55. The validity of DSM-IV cannabis abuse and dependence criteria in adolescents and the value of additional cannabis use indicators. Piontek D; Kraus L; Legleye S; Bühringer G Addiction; 2011 Jun; 106(6):1137-45. PubMed ID: 21205060 [TBL] [Abstract][Full Text] [Related]
56. The DSM Guided Cannabis Screen (DSM-G-CS): description, reliability, factor structure and empirical scoring with a clinical sample. Alexander D; Leung P Addict Behav; 2011 Nov; 36(11):1095-100. PubMed ID: 21741769 [TBL] [Abstract][Full Text] [Related]
57. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Adamson SJ; Sellman JD Drug Alcohol Rev; 2003 Sep; 22(3):309-15. PubMed ID: 15385225 [TBL] [Abstract][Full Text] [Related]
58. Validation and Invariance of the Dental Anxiety Scale in a Brazilian sample. Bonafé FS; Campos JA Braz Oral Res; 2016 Dec; 30(1):e138. PubMed ID: 28001246 [TBL] [Abstract][Full Text] [Related]
60. Tell me who your friends are?! The mediating role of friends' use in cannabis abuse. Dias PC; Lopes S; Garcia Del Castillo JA Trends Psychiatry Psychother; 2022 May; 44(Suppl 1):e20210269. PubMed ID: 34800359 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]